Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.

You Browsed By:

You Searched For:

The product image can not be displayed.



Mark Gray

Managing Director - US/Americas Corporate Finance

US and Americas

Tom Marshella
Managing Director - US/Americas Corporate Finance

Paloma San Valentin
Managing Director - US/Americas Corporate Finance


Myriam Durand
Managing Director- EMEA Corporate Finance

Philipp Lotter
Managing Director- EMEA Corporate Finance

Asia Pacific

Brian Cahill
Managing Director - Asia Pacific Corporates/Financial Institutions​​​​


The product image can not be displayed.

Research and analysis on public companies and their debt instruments.



  • 29 Apr 2016
    • Outlook for US broadcast television remains stable
      The stable outlook for the industry reflects seven consecutive years of US economic growth, which underpins advertising and broadcast revenue gains. We expect increasing demand for political advertising to mute core ad growth during the presidential cycle, but political spending will boost broadcasters’ overall ad revenues by 14%-18%... Press Release l Full Report
  • 28 Apr 2016
    • Negative industry outlooks outnumber positive as growth expectations weaken
      Our roster of industry sector outlooks crossed into negative territory during the first quarter of this year, a signal that clashes with the ongoing rally in the high-yield market. One quarter of our 52 outlooks worldwide are now negative, and negative outlooks outnumber positive for the first time since 2013. The global commodities-oriented sectors, particularly oil/gas and metals/mining, continue to struggle, with one-year default forecasts rising... Full Report
  • 26 Apr 2016
    • Strong industry fundamentals will keep global pharmaceutical growth steady amid cost containment efforts
      Increasing use of prescription drugs combined with favorable pricing for US branded drugs and merger-related synergies will keep global pharmaceutical earnings growth steady despite worldwide efforts to contain costs. Our stable industry outlook also considers good pipeline momentum and manageable patent expirations over the next 12-18 months. Although biosimilars will continue to gain traction, the revenue cliff risk for biotech products is relatively low….Press Release l Full Report
Please refine your search by Market Segment to get corresponding Rating Activity and Watchlist
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry